Emergent BioSolutions Awarded Department of National Defence Contract to Supply Anthrasil to the Canadian Government
December 12 2017 - 7:00AM
Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has
been awarded a contract by the Department of National Defence (DND)
valued at approximately $8 million to deliver Anthrasil® (Anthrax
Immune Globulin Intravenous [human]) to the Canadian government.
This contract award follows the recent approval of Anthrasil by
Health Canada under the Extraordinary Use New Drug (EUND)
Regulations, which provide a regulatory pathway for products for
which collecting clinical information for its intended use in
humans is logistically or ethically not possible. Anthrasil is
indicated for the treatment of inhalational anthrax in adult and
pediatric patients in combination with appropriate antibacterial
drugs.
“Receiving Health Canada approval of Anthrasil and being awarded
the DND procurement contract reflect the Canadian government’s
continued commitment to anthrax preparedness. Anthrax remains on
the Canadian government’s list of top biological agents given its
potential to be used in a bioterrorist attack,” said Dr. Laura
Saward, senior vice president and antibody therapeutics business
unit head at Emergent BioSolutions. “Emergent has a longstanding
history and successful track record of partnering with governments
to provide preparedness solutions in the form of critical medical
countermeasures for these serious public health threats.”
Emergent received U.S. Food and Drug Administration approval for
Anthrasil in 2015 and has delivered more than 10,000 doses of
Anthrasil to the U.S. Strategic National Stockpile. It is the only
polyclonal antibody therapeutic available in the U.S. and Canada
for treating inhalational anthrax.
About Emergent BioSolutionsEmergent
BioSolutions Inc. is a global life sciences company seeking to
protect and enhance life by focusing on providing specialty
products for civilian and military populations that address
accidental, intentional, and naturally emerging public health
threats. Through our work, we envision protecting and enhancing 50
million lives with our products by 2025. Additional information
about the company may be found at www.emergentbiosolutions.com.
Follow us on Twitter @emergentbiosolu and Instagram
@life_at_emergent.
Safe Harbor StatementThis press release
includes forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Any statements,
other than statements of historical fact, including statements
containing the words “believes,” “expects,” “anticipates,”
“intends,” “plans,” “estimates” and similar expressions, are
forward-looking statements. These forward-looking statements are
based on our current intentions, beliefs and expectations regarding
future events. We cannot guarantee that any forward-looking
statement will be accurate. Investors should realize that if
underlying assumptions prove inaccurate or unknown risks or
uncertainties materialize, actual results could differ materially
from our expectations. Investors are, therefore, cautioned not to
place undue reliance on any forward-looking statement. Any
forward-looking statement speaks only as of the date of this press
release, and, except as required by law, we do not undertake to
update any forward-looking statement to reflect new information,
events or circumstances.
There are a number of important factors that could cause the
company’s actual results to differ materially from those indicated
by such forward-looking statements, including availability of
funding for our Canadian and U.S. government grants and contracts
and our manufacturing capabilities and strategy. The foregoing sets
forth many, but not all, of the factors that could cause actual
results to differ from our expectations in any forward-looking
statement. Investors should consider this cautionary statement, as
well as the risk factors identified in our periodic reports filed
with the SEC, when evaluating our forward-looking statements.
Investor Contact:Robert G.
BurrowsVice President, Investor
Relations240-631-3280BurrowsR@ebsi.com
Media Contact:Lynn KiefferVice
President, Corporate
Communications240-631-3391KiefferL@ebsi.com
Emergent Biosolutions (NYSE:EBS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Emergent Biosolutions (NYSE:EBS)
Historical Stock Chart
From Apr 2023 to Apr 2024